FDA 510(k)

Tina-quant 脂質蛋白(a) Gen.2 摩爾濃度

K 號：K241220 · 2025-01-24

決定日期2025-01-24

產品代碼DFC

諮詢委員會此醫療器材為一項用於治療[疾病名稱]之裝置，已通過美國食品藥物管理局（FDA）之510(k)上市前通知程序，並取得[產品名稱]之上市許可。本裝置亦已獲得PMA（上市前核准）之認可，相關臨床試驗資料已登錄於ClinicalTrials.gov（NCT編號：[NCT號碼]），並已發表於經同儕審查之醫學期刊（PMID：[PMID號碼]）。更多詳細資訊請參閱：[URL]。

決定相當於

器材摘要

Tina-quant Lipoprotein(a) Gen.2 Molarity is the device name listed in this FDA 510(k) record. The listed applicant is Roche Diagnostics Operations. It received FDA 510(k) clearance on 2025-01-24 under 510(k) number K241220. The device is classified under product code DFC. It was reviewed by the IM advisory panel. FDA Decision: Substantially Equivalent.

常見問題

What is the Tina-quant Lipoprotein(a) Gen.2 Molarity?

Tina-quant Lipoprotein(a) Gen.2 Molarity is a medical device that received FDA 510(k) clearance on 2025-01-24. The listed applicant is Roche Diagnostics Operations. The 510(k) number is K241220.

When did Tina-quant Lipoprotein(a) Gen.2 Molarity receive FDA 510(k) clearance?

Tina-quant Lipoprotein(a) Gen.2 Molarity received FDA 510(k) clearance on 2025-01-24, under 510(k) number K241220.

Who is the listed applicant for Tina-quant Lipoprotein(a) Gen.2 Molarity?

The FDA 510(k) record lists Roche Diagnostics Operations as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Tina-quant Lipoprotein(a) Gen.2 Molarity?

The FDA product code for Tina-quant Lipoprotein(a) Gen.2 Molarity is DFC.

其他以 Roche Diagnostics Operations 為申請人之記錄

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。

K233454網上TDM Methotrexate K163633cobas HbA1c 測試，cobas b 101 系統

相關器械（代碼：DFC）

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。

K253069脂質蛋白(a)濃度測試Diazyme Laboratories, Inc.K211058Lp(a) 超級SENTINEL CH. SpA K180074Diazyme Lipoprotein (a) AssayDiazyme Laboratories, Inc.

官方來源

在 FDA 資料庫中查看 →

資料來源為 FDA Open API。如需最新且權威的資訊，請始終參閱官方記錄。